Instil Bio annual stock-based compensation
2020
2021
2022
2023
2024
2025
Instil Bio Stock-Based Compensation Growth & History (TIL)
Instil Bio's stock-based compensation was $8.7M for fiscal 2025.
View full Instil Bio company overviewInstil Bio annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $8.7M | −$8.6M | −49.63% |
| 2024 | 2024-12-31 | $17.3M | −$909,000 | −5.00% |
| 2023 | 2023-12-31 | $18.2M | −$12.3M | −40.32% |
| 2022 | 2022-12-31 | $30.4M | $4.2M | +16.20% |
| 2021 | 2021-12-31 | $26.2M | $24.5M | +1435.58% |
| 2020 | 2020-12-31 | $1.7M | — | — |
Instil Bio quarterly stock-based compensation
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.0M | −$788,000 | −43.20% |
| Q1 2026 | 2026-03-31 | $985,000 | −$2.5M | −71.82% |
| Q4 2025 | 2025-12-31 | $1.6M | −$2.9M | −64.32% |
| Q3 2025 | 2025-09-30 | $1.8M | −$2.3M | −56.54% |
| Q2 2025 | 2025-06-30 | $1.8M | −$2.3M | −56.29% |
| Q1 2025 | 2025-03-31 | $3.5M | −$1.0M | −22.59% |
| Q4 2024 | 2024-12-31 | $4.5M | −$52,000 | −1.14% |
| Q3 2024 | 2024-09-30 | $4.1M | −$602,000 | −12.89% |
| Q2 2024 | 2024-06-30 | $4.2M | −$240,000 | −5.44% |
| Q1 2024 | 2024-03-31 | $4.5M | −$15,000 | −0.33% |
| Q4 2023 | 2023-12-31 | $4.6M | −$2.1M | −31.46% |
| Q3 2023 | 2023-09-30 | $4.7M | −$3.3M | −41.49% |
| Q2 2023 | 2023-06-30 | $4.4M | −$3.9M | −46.98% |
| Q1 2023 | 2023-03-31 | $4.5M | −$3.0M | −39.54% |
| Q4 2022 | 2022-12-31 | $6.6M | −$2.3M | −25.39% |
| Q3 2022 | 2022-09-30 | $8.0M | −$754,000 | −8.63% |
| Q2 2022 | 2022-06-30 | $8.3M | $2.6M | +44.87% |
| Q1 2022 | 2022-03-31 | $7.5M | $4.7M | +166.47% |
| Q4 2021 | 2021-12-31 | $8.9M | $8.5M | +2045.54% |
| Q3 2021 | 2021-09-30 | $8.7M | $8.4M | +2547.27% |
| Q2 2021 | 2021-06-30 | $5.7M | $4.8M | +539.04% |
| Q1 2021 | 2021-03-31 | $2.8M | $2.8M | +4435.48% |
| Q4 2020 | 2020-12-31 | $415,000 | — | — |
| Q3 2020 | 2020-09-30 | $330,000 | — | — |
| Q2 2020 | 2020-06-30 | $899,000 | — | — |
| Q1 2020 | 2020-03-31 | $62,000 | — | — |
Instil Bio stock-based compensation trends
Over the last five fiscal years, Instil Bio's stock-based compensation increased from $1.7M to $8.7M, a change of $7.0M. The latest reported quarter, Q2 2026, shows $1.0M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Instil Bio source filings ↗